6533b82efe1ef96bd12932b3
RESEARCH PRODUCT
Associations of neuropsychiatric symptoms and antidepressant prescription with survival in Alzheimer's disease
Jonathan HuntleyBrendon StubbsNicola VeroneseAndrew SommerladChristoph MuellerChristoph MuellerGayan PereraAndré F. CarvalhoRobert Stewartsubject
Malemedicine.medical_specialtyPediatricsDatabases FactualDementia; antidepressants; depression; mortalityKaplan-Meier EstimateNeuropsychological TestsRisk AssessmentSeverity of Illness Index03 medical and health sciencesSex Factors0302 clinical medicineAlzheimer DiseasemedicineHumansDementia030212 general & internal medicineMedical prescriptionRisk factorPsychiatryGeneral NursingDepression (differential diagnoses)AgedProportional Hazards ModelsRetrospective StudiesAged 80 and overDepressive Disorderbusiness.industryHealth PolicyHazard ratioAge FactorsGeneral MedicineMiddle AgedPrognosismedicine.diseaseSurvival AnalysismortalityAntidepressive AgentsConfidence intervalantidepressantsdepressionCohortFemaleDementiaGeriatrics and GerontologyAlzheimer's diseasebusinessdementia mortality030217 neurology & neurosurgerydescription
Objective Depression is associated with increased mortality in community samples. The use of antidepressant medication may also increase mortality, however, it is still unclear whether taking antidepressants before or after a diagnosis of dementia influences survival. Design Retrospective. Setting A cohort with a diagnosis of Alzheimer disease (AD) from a large mental health and dementia care database in South London, linked to hospitalization and mortality data. Participants Mild dementia (Mini-Mental State Examination ≥18/30) at the point of diagnosis. Measurements We ascertained antidepressant prescription, either in the 6 months before or after dementia diagnosis, and used the HoNOS65+, a standard clinician-rated measure of patient well-being, to determine depression severity and other neuropsychiatric, physical health, and functional difficulties. We conducted a survival analysis, adjusted for potential confounders and addressed possible confounding by indication through adjusting for a propensity score. Results Of 5473 patients with AD, 22.8% were prescribed an antidepressant in a 1-year window around dementia diagnosis. Of these, 2415 (44.1%) died in the follow-up period [mean (standard deviation) 3.5 (2.4) years]. Prescription of an antidepressant, both before and after dementia diagnosis, was significantly associated with higher mortality after adjusting for a broad range of potential confounders including symptom severity, functional status, and physical illness (hazard ratio 1.22; 95% confidence interval 1.08–1.37 for prescription prior to dementia diagnosis; 95% confidence interval 1.04–1.45 for prescription post dementia diagnosis). In stratified analyses, risks remained significant in those without neuropsychiatric symptoms. Conclusions The prescription of antidepressants around the time of dementia diagnosis may be a risk factor for mortality. © 2017 AMDA – The Society for Post-Acute and Long-Term Care Medicine
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 |